Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Voyager Therapeutics (VYGR) PT Lowered to $27 at Baird
November 8, 2018 8:44 AM ESTBaird analyst Brian Skorney lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $27.00 (from $31.00) while maintaining a Outperform rating.
The analyst commented, "After initially indicating that the Phase 2 study Voyager is about to start could be fileable, the FDA recently notified Voyager... More
